Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03659747
Other study ID # NH-03977
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 11, 2018
Est. completion date December 21, 2018

Study information

Verified date March 2019
Source Danisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of the study is to investigate the effect of probiotic supplementation on lactose maldigestion.


Description:

Primary endpoint is defined as the difference in breath hydrogen concentration (BHC, ppm) in lactase and probiotic groups compared to placebo and non-inferiority in breath hydrogen concentration (BHC, ppm) in probiotic group compared to lactase group, measured by the incremental area under curve (iAUC) analysis.

To characterize the benefit of the investigational product (IP) the following secondary endpoints will be analyzed:

Breath test:

- Breath hydrogen peak value (ppm) in lactase and probiotic groups compared to placebo

- Cumulative breath hydrogen (ppm) in lactase and probiotic groups compared to placebo

Acute gastrointestinal symptoms (severity or presence/absence to be defined on a Likert scale) in lactase and probiotic groups compared to placebo:

- Abdominal pain

- Flatulence

- Bloating

- Nausea and vomiting

- Bowel movements and diarrhea (if present, stool consistency to be defined on Bristol stool scale and number of bowel movements to be recorded)

Ancillary:

- Baseline fasting BHC (ppm)

- Breath methane (CH4; ppm)

- Breath carbon dioxide (CO2; ppm)

- Probiotic identification in feces before each lactose challenge by molecular methods

- Gene test to determine lactase deficiency status at V1 (following single nucleotide polymorphism (SNP) variants to be screened: -13910*C (Europe, Central Asia, commonly used) -13915*T (Saudi-Arabia, Africa), -14010*C (Africa), -13907*C (Africa))


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date December 21, 2018
Est. primary completion date December 21, 2018
Accepts healthy volunteers No
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria:

1. Voluntary, written, informed consent to participate in the study

2. Agreement to comply with the protocol and study restrictions

3. Healthy females and males of age 25 to 60 years (inclusive)

4. Self-declared or medically diagnosed lactose intolerance

5. Increase of more than 20 ppm in breath hydrogen within 3 h from the baseline fasting breath hydrogen value at V2

6. Participants who agree to maintain their usual dietary habits throughout the trial period

7. Participants who agree not to consume probiotics, prebiotics, fermented milk, and/or yogurt containing probiotics during and two weeks before Visit 3 (2 weeks after pre-screening visit)

8. Females of child-bearing potential who agree to use a medically approved methods of birth control

9. Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects

10. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research

Exclusion Criteria:

1. Gastrointestinal disorder or disease (e.g. Crohn's disease, ulcer, irritable bowel syndrome (IBS), Celiac disease, small intestinal bacterial overgrowth (SIBO), pancreatitis and disorders affecting gastrointestinal motility)

2. Diagnosed type 1 or type 2 diabetes

3. Prior abdominal surgery that, in the opinion of the investigator, may present a risk for the participant or affect study results

4. Ongoing or recent (last 1 months) antibiotic treatment.

5. Use of laxatives or drugs known to affect gut motility 1 month preceding the screening visit and during the study

6. Ongoing or recurrent use of proton pump inhibitors

7. Colonoscopy within 3 months before screening

8. History of recurrent colon cleansing and/or a colon cleansing within 3 months before screening

9. Gastrointestinal infection within 1 month before screening or during the trial

10. Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may affect the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness)

11. History of diagnosed coronary heart disease/cardiovascular disease or artificial heart valve.

12. Any obstructive or restrictive respiratory syndrome/disease that may impact breath test (e.g. asthma or chronic obstructive pulmonary disease (COPD))

13. Use of tobacco, snuff, nicotine and e-cigarette

14. History of or current abuse of drugs, alcohol or medication (self- reported)

15. Self-declared use of illicit drugs

16. Pregnant or lactating female, or pregnancy planned during study period

17. Participants under administrative or legal supervision.

18. Participation in another study with any investigational product within 60 days of screening

19. Abnormal values in safety blood tests at V1 i.e. clinically significant or >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome)

20. Other reasons that, in the opinion of the Investigator, make the participant unsuitable for enrolment

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic
- 6 g sachet containing probiotic powder (1.8 x 10^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
Lactrase
- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
Other:
Placebo
- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.

Locations

Country Name City State
Germany analyze & realize GmbH Berlin

Sponsors (2)

Lead Sponsor Collaborator
Danisco Analyze & Realize

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Difference in baseline fasting BHC (ppm) between the treatments approximately 40 days
Other Difference in breath methane concentration (ppm) between the treatments approximately 40 days
Other Difference in breath carbon dioxide concentration (ppm) between the treatments approximately 40 days
Other Difference in the quantity of probiotic in fecal samples between the treatments approximately 40 days
Other Description of the SNP variants in each treatment group approximately 40 days
Primary Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by the iAUC analysis approximately 40 days
Primary Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by the iAUC analysis approximately 40 days
Primary Non-inferiority in breath hydrogen concentration (BHC, ppm) of probiotic group compared to lactase group (positive control), measured by the iAUC analysis approximately 40 days
Secondary Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by breath hydrogen peak value approximately 40 days
Secondary Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by breath hydrogen peak value approximately 40 days
Secondary Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by cumulative breath hydrogen value approximately 40 days
Secondary Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by cumulative breath hydrogen value approximately 40 days
Secondary Difference in the presence of diarrhea in lactase group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the presence of diarrhea in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of abdominal pain in lactase group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of abdominal pain in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of flatulence in lactase group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of flatulence in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of bloating in lactase group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of bloating in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of nausea in lactase group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the severity of nausea in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the presence of vomiting in lactase group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the presence of vomiting in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the presence of bowel movements in lactase group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
Secondary Difference in the presence of bowel movements in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey approximately 40 days
See also
  Status Clinical Trial Phase
Completed NCT05831527 - An Exploratory Investigation of a Supplement to Promote Gut Health N/A
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Completed NCT02054455 - Proton Pump Inhibitors and Gastrointestinal Symptoms Phase 4
Completed NCT03959722 - The Effect of Probiotics on GI Symptoms N/A
Recruiting NCT03514784 - Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder Phase 1/Phase 2
Completed NCT01927900 - The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy Volunteers N/A
Recruiting NCT04919265 - Mother-Infant Cohort Study in Malaysia and China
Completed NCT01171014 - Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms Phase 2/Phase 3
Completed NCT00574197 - Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients Phase 4
Recruiting NCT03403387 - Effects of GlutenShield, a Prebiotic, Probiotic, and Enzyme Supplement, on the Gut Microbiome of Adults With GI Symptoms N/A
Completed NCT01964599 - Potato Fiber and Gastrointestinal Function: Phase 3 N/A
Recruiting NCT06248177 - Probiotic Effect on Gastrointestinal Symptoms (FLORABIOTIC REFUERZO). N/A
Withdrawn NCT04228003 - Pendulum D2D Glucose Control for Adults With Type 2 Diabetes N/A
Recruiting NCT06425094 - Effects of a Microalgae Extract Dietary Supplement on Gut Health, Anxiety, and Immune Function Phase 1
Completed NCT03714464 - Effect of Physical Form of Apples on Gastrointestinal Function and Satiety: a MRI Study N/A
Active, not recruiting NCT03696953 - The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization. Phase 2
Completed NCT02277431 - Probiotic Supplementation Among Adults With Recurrent Gastrointestinal Symptoms Phase 2/Phase 3
Completed NCT00677378 - Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain N/A
Completed NCT03685552 - Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0 N/A
Completed NCT01184456 - A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System Phase 2